A detailed history of Two Sigma Investments, LP transactions in Morpho Sys Ag stock. As of the latest transaction made, Two Sigma Investments, LP holds 112,957 shares of MOR stock, worth $2.06 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
112,957
Previous 185,927 39.25%
Holding current value
$2.06 Million
Previous $1.84 Million 11.36%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$8.6 - $18.18 $627,542 - $1.33 Million
-72,970 Reduced 39.25%
112,957 $2.05 Million
Q4 2023

Feb 14, 2024

BUY
$4.55 - $9.9 $845,967 - $1.84 Million
185,927 New
185,927 $1.84 Million
Q2 2023

Aug 14, 2023

BUY
$3.95 - $7.74 $98,560 - $193,128
24,952 New
24,952 $186,000
Q1 2022

May 16, 2022

SELL
$5.87 - $9.73 $291,322 - $482,890
-49,629 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$9.08 - $12.45 $237,405 - $325,517
26,146 Added 111.34%
49,629 $468,000
Q3 2021

Nov 15, 2021

SELL
$11.76 - $19.51 $168,614 - $279,734
-14,338 Reduced 37.91%
23,483 $276,000
Q2 2021

Aug 16, 2021

BUY
$18.95 - $23.95 $716,707 - $905,812
37,821 New
37,821 $728,000
Q4 2019

Feb 14, 2020

SELL
$26.07 - $36.32 $198,705 - $276,831
-7,622 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$24.18 - $31.58 $184,299 - $240,702
7,622 New
7,622 $209,000
Q1 2019

May 15, 2019

SELL
$22.55 - $29.84 $194,110 - $256,862
-8,608 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$21.96 - $31.02 $189,031 - $267,020
8,608 New
8,608 $217,000
Q3 2018

Nov 14, 2018

SELL
$26.64 - $35.66 $259,393 - $347,221
-9,737 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$25.15 - $30.6 $244,885 - $297,952
9,737 New
9,737 $295,000

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Market Cap $2.49B
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.